Salado-Burbano JC, Eskenazi-Betech R, Halabe-Cherem J

Language: Spanish
References: 51
Page: 634-647
PDF size: 483.85 Kb.

ABSTRACT

Recurrent fevers make up a significant yet underappreciated proportion (18-42%) of fevers of unknown origin. A group of recurrent fevers, known as autoinflammatory diseases or hereditary periodic fever syndromes occur due to a deregulated response of innate immunity, whereby an autoinflammatory reaction occurs resulting in tissue damage. Unlike autoimmune diseases, the autoinflammatory diseases are not associated to specific autoantibodies or major histocompatibility complexes (MHCs), but rather result from an aberrant activation of innate immune cells such as macrophages and neutrophils. Although the majority of cases begin during childhood, several are often diagnosed years after their debut or begin during adult life, justifying the need for internists to be familiar with these diseases. In this review we discuss the epidemiology, pathophysiology, clinical presentation, diagnosis and management of the main autoinflammatory diseases.

REFERENCES

1. Cunha BA. Fever of unknown origin: Clinical overview of classic and current concepts. Infect Dis Clin North Am 2007;21(4):867-915.

2. Knockaert DC. Recurrent fevers of unknown origin. Infect Dis Clin N Am 2007;21:1189-1211.

3. De Kleijn EMH, Vandenbroucke JP, Van der Meer JWM. Fever of unknown origin (FUO) II: diagnostic procedures in a prospective multicenter study in 167 patients. Medicine 1997;76:401-414.

4. Knockaert DC, Vanneste LJ, Bobbaers HJ. Recurrent or episodic fever of unknown origin. Review of 45 cases and survey of the literature. Medicine 1993;72:184-196.

5. Zenone T. Démarche diagnostique des fièvres récurrentes prolongées chez l’adulte. Rev Med Interne 2015;36(7):457- 466.

6. Le Moing V, Leport C. Fièvres intermittentes d’origine infectieuse. Rev Prat 2002;52:139-144.

7. Ben-Chetrit E, Touitou I. Familial Mediterranean Fever in the world. Arthritis Rheum 2009; 61:1447.

8. Livneh A. Reported at Familial Mediterranean Fever (FMF) and Beyond: The 4th International Congress on Systemic Autoinflammatory Diseases, November 6-10, 2005, Bethesda, Maryland.

9. Manukyan G, Aminov R. Update on pyrin functions and mechanisms of familial Mediterranean fever. Front. Microbiol 2016;7:456.

10. Van Der Hilst JCH, Simon A, Drenth JPH. Hereditary periodic fever and reactive amyloidosis. Clin Exp Med 2005;5:87-98.

11. Halabe Cherem J, Rábago Arredondo J. Non-surgical acute abdomen as a clinical expression of Mediterranean familial fever. Rev Invest Clin 2007;59(3):212-218.

12. Moreno Del Castillo MC, Gómez Romero P, Ángel Juárez VM, Halabe Cherem J. Dolor torácico y disnea como manifestaciones iniciales de fiebre mediterránea familiar. Reporte de caso. An Med (Mex) 2014;59(2):148-152.

13. Halabe Cherem J, Hamui Sutton A, Cohen Cohen S, Sacal Dumani E, et al. Pericarditis recidivante y fiebre mediterránea familiar. Rev Med Inst Mex Seguro Soc 2009;47(2):211-214.

14. Halabe Cherem J, Islas Andrade S, Lifshitz A, Nellen H. Persistent fever as the only symptom of familial Mediterranean fever. Arch Intern Med 1990;150:1347.

15. Halabe Cherem J, Nellen Hummel H, Flores Padilla G, Mercado Atri M, Pizutto Chávez J. Familial Mediterranean fever and primary antiphospholipid syndrome, a rare association - A case report. J Vasc Dis 1995;46(9):859-861.

16. Halabe Cherem J, Pérez Jiménez C, Nellen Hummel H, Mercado Atri M, Sigala Rodríguez C, Castañón González J. Fiebre mediterránea familiar en la Ciudad de México. Seguimiento por 20 años. Cir Ciruj 2004;72:135-138.

17. Livneh A, Langevitz P, Zemer D, et al. Criteria for the diagnosis of familial Mediterranean fever. Arthritis Rheum 1997;40:1879.

18. Berkun Y, Eisenstein EM. Update on auto-inflammatory diseases and familial Mediterranean fever. IMAJ 2016;18:221-224.

19. Hull KM, Drewe E, Aksentijevich I, Singh HK, Wong K, Mc- Dermott EM, et al. The TNF receptor-associated periodic syndrome (TRAPS): emerging concepts of an autoinflammatory disorder. Medicine (Baltimore) 2002;81(5):349-368.

20. Turner MD, Chaudhry A, Nedjai B. Tumor necrosis factor receptor trafficking dysfunction opens the TRAPS door to pro-inflammatory cytokine secretion. Biosci Rep 2012;32:105-112.

21. Lachmann HJ, Papa R, Gerhold K, Obici L, et al. The phenotype of TNF receptor-associated autoinflammatory syndrome (TRAPS) at presentation: a series of 158 cases from the Eurofever/EUROTRAPS international registry. Ann Rheum Dis 2014;73:2160-2167.

22. Federici S, Sormani MP, Ozen S, Lachmann HJ, et al. Evidence-based provisional clinical classification criteria for autoinflammatory periodic fevers. Ann Rheum Dis 2015;74(5):799-805.

23. Bulua AC, Mogul DB, Aksentijevich I, et al. Efficacy of etanercept in the tumor necrosis factor receptor-associated periodic syndrome: a prospective, open-label, dose-escalation study. Arthritis Rheum 2012;64(3):10.1002/art.33416.

24. Nedjai B, Hitman GA, Quillinan N, et al. Proinflammatory action of the antiinflammatory drug infliximab in tumor necrosis factor receptor-associated periodic syndrome. Arthritis Rheum 2009;60(2):619-625.

25. Krelenbaum M, Chaiton A. Successful treatment with infliximab of a patient with tumor necrosis factor-associated periodic syndrome (TRAPS) who failed to respond to etanercept. J Rheumatol 2010;37(8):1780-1782.

26. Grimwood C, Despert V, Jeru I, Hentgen V. On-demand treatment with anakinra: a treatment option for selected TRAPS patients. Rheumatology 2015;54(9):1749-1751.

27. Brizi MG, Galeazzi M, Lucherini OM, et al. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome with canakinumab. Ann Intern Med 2012;156(12):907-908.

28. Akasbi N, Soyfoo MS. Successful treatment of tumor necrosis factor receptor-associated periodic syndrome (TRAPS) with tociliizumab: A case report. Eur J Rheumatol 2015;2(1):35-36.

29. Simon A, Mariman EC, Van Der Meer JWM, Drenth JPH. A Founder Effect in the hyperimmunoglobulinemia D and periodic fever syndrome. Am J Med 2003;114:148-152.

30. Kellner U, Stöhr H, Weinitz S, Farmand G, Weber BHF, Mevalonate kinase deficiency associated with ataxia and retinitis pigmentosa in two brothers with MVK gene mutations. Ophtalmic Genet 2017:1-5.

31. Houten SM, Frenkel J, Waterham HR. Isoprenoid biosynthesis in hereditary periodic fever syndromes and inflammation. Cell Mol Life Sci 2003;60:1118.

32. Zhang S. Natural history of mevalonate kinase deficiency: a literature review. Pediatr Rheumatol Online J 2016;14(1):30.

33. Ter Haar NM, Jeyaratnam J, Lachmann HJ, Simon A, Brogan PA, Doglio M, et al. The phenotype and genotype of mevalonate kinase deficiency. Arthritis Rheumatol 2016;68(11):2795-2805.

34. Favier LA, Schulert GS. Mevalonate kinase deficiency: current perspectives. Appl Clin Genet 2016;9:101-110.

35. Cuisset L, Jeru I, Dumont B, Fabre A, Cochet A, Le Bozec J, et al. Mutations in the autoinflammatory cryopyrinassociated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis 2011;70:495-499.

36. Sarrabay G, Grandemange S, Touitou I. Diagnosis of cryopyrin-associated periodic syndrome: challenges, recommendations and emerging concepts. Expert Rev Clin Immunol 2015;11(7):827-835.

37. Drenth JPH, van der Meer JWM. The inflammasome - A linebacker of innate defense. N Engl J Med 2006;355(7):730- 732.

38. Levy R, Gérard L, Kuemmerle-Deschner J, Lachmann HJ, Koné-Paut I, Cantarini L, et al. Phenotypic and genotypic characteristics of cryopyrin-associated periodic syndrome: a series of 136 patients from the Eurofever Registry. Ann Rheum Dis 2014;74(11):2043-2049.

39. Koné-Paut I, Galeotti C. Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome. Expert Rev Clin Immunol 2015;11(10):1083- 1092.

40. Forsvoll J, Kristoffersen EK, Oymar K. Incidence, clinical characteristics and outcome in Norwegian children with periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome;a population-based study. Acta Paediatr 2013;102:187-192.

41. Padeh S, Stoffman N, Berkun Y. Periodic fever accompanied by aphthous stomatitis, pharyngitis and cervical adenitis syndrome (PFAPA syndrome) in adults. Isr Med Assoc J 2008;10:358-360.

42. Kraszewska-Głomba B, Matkowska-Kocjan A, Szenborn L. The pathogenesis of periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis syndrome: A review of current research. Mediators Inflamm 2015;2015:563876.

43. Theodoropoulou K, Vanoni F, Hofer M. Periodic fever, aphthous stomatitis, pharyngitis, and cervical adenitis (PFAPA) syndrome: A review of the pathogenesis. Curr Rheumatol Rep 2016;18(4):18.

44. Wekell P, Karlsson A, Berg S, Fasth A. Review of autoinflammatory diseases, with a special focus on periodic fever, aphthous stomatitis, pharyngitis and cervical adenitis syndrome. Acta Paediatr 2016;105:1140-1151.

45. Thomas KT, Feder HM, Lawton AR, Edwards KM. Periodic fever syndrome in children. J Pediatr 1999;135:15-21.

46. Rigante D, Vitale A, Natale MF, Lopalco G, et al. A comprehensive comparison between pediatric and adult patients with periodic fever, aphthous stomatitis, pharyngitis, and cervical adenopathy (PFAPA) syndrome. Clin Rheumatol 2016 [Epub ahead of print].

47. Dale DC, Person RE, Bolyard AA, Aprikyan AG, et al. Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropenia. Blood 2000;96:2317-2322.

48. Vanoni F, Theodoropoulou K, Hofer M. PFAPA syndrome: a review on treatment and outcome. Pediatr Rheumatol Online J 2016;14(1):38.

49. Hernández-Rodríguez J, Ruíz-Ortiz E, Tomé A, Espinosa G, et al. Clinical and genetic characterization of the autoinflammatory diseases diagnosed in an adult reference center. Autoimmune Rev 2016;15(1):9-15.

50. Giannina Gaslini Institute. Eurofever Classification Criteria. [Internet]. Disponible en: .

51. Piram M, Koné-Paut I, Lachmann HJ, Frenkel J, et al. Validation of the Autoinflammatory Diseases Activity Index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis 2014;73:2168-2173.